Abstract: Objective To investigate the effects of Guanxinning tablet combined with clopidogrel on blood lipids, cardiac function, and hemorheological indicators in patients with coronary atherosclerotic heart disease (CHD) after percutaneous coronary intervention (PCI). Methods A total of 160 post-PCI CHD patients admitted to Zhejiang Qingchun Hospital from August 2022 to December 2023 were randomly divided into a control group (conventional Western medicine treatment) and an intervention group (conventional Western medicine treatment plus Guanxinning tablet), using a random number table, with 80 patients in each. The clinical efficacy was compared between the two groups. Results After 6 months of follow-up, the total effective rate in the intervention group was significantly higher than that in the control group (two-sided P ＜ 0.05). After 3 months of treatment and at 6-month follow-up, the inflammatory factor indicators (tumor necrosis factor-α, C-reactive protein), blood lipid indicators (triglycerides, low-density lipoprotein, total cholesterol, and high-density lipoprotein), hemorheological indicators (whole blood high-shear viscosity, platelet aggregation rate, plasma viscosity), and cardiac function indicators (left ventricular ejection fraction, wall motion score index, and left ventricular end-systolic diameter) in both groups were significantly improved compared with those before treatment (two-sided P ＜ 0.05). Meanwhile, the improvement in the above indicators in the intervention group was more significant than that in the control group (two-sided P ＜ 0.05). At 6-month follow-up, the above indicators in both groups showed significant improvement compared with those at 3 months of treatment (two-sided P ＜ 0.05). There was no statistically significant difference in the total incidence of adverse reactions between the two groups (P ＞ 0.05). Conclusion Guanxinning tablet combined with clopidogrel can improve blood lipids, cardiac function, and hemorheological indicators, while alleviating the inflammatory response in post-PCI CHD patients, demonstrating a favorable clinical efficacy.